Humanexome 12 v1.1 or v1 2 dna analysis beadchip

Methods for collection and extraction of genomic DNA samples were described previously [62 (link)]. All EWASs (Supplementary Figure 5) were performed with the use of the HumanExome-12 v1.1 or v1.2 DNA Analysis BeadChip or Infinium Exome-24 v1.0 BeadChip (Illumina, San Diego, CA, USA). Detailed information of these exome arrays and methods of quality control were described previously [62 (link)]. Totals of 41,352 SNPs (eGFR, serum creatinine concentration, CKD) or 41,372 SNPs (serum uric acid concentration, hyperuricemia) that passed quality control were analyzed.

Methods for sample collection and extraction of genomic DNA have been described previously [31 (link)]. EWASs for FPG concentration and blood HbA_1c content included 11,729 and 8635 subjects, respectively, whereas that for type 2 DM included 14,023 individuals (3573 subjects with type 2 DM, 10,450 controls). Data for FPG levels were obtained from subjects who had fasted overnight. Data for blood HbA_1c content were obtained from subjects with type 2 DM or impaired glucose tolerance or from those who had annual health checkup. The EWASs were performed with the use of a HumanExome-12 v1.1 or v1.2 DNA Analysis BeadChip or Infinium Exome-24 v1.0 BeadChip (Illumina, San Diego, CA, USA). Detailed information of the exome arrays and methods of quality control have been described previously [31 (link)]. Genotype data were examined for population stratification by principal components analysis [35 (link)] (Supplementary Figure 3). A total of 41,265 SNPs passed quality control and was subjected to analysis.

Methods for collection and extraction of genomic DNA samples were described previously [40 (link)]. EWASs for the serum concentrations of triglycerides (13,414 subjects), HDL-cholesterol (14,119 subjects), or LDL-cholesterol (13,577 subjects) or for hypertriglyceridemia (4742 cases, 8672 controls), hypo–HDL-cholesterolemia (2646 cases, 11,473 controls), or hyper-LDL-cholesterolemia (4489 cases, 9088 controls) were performed with HumanExome-12 v1.1 or v1.2 DNA Analysis BeadChip or Infinium Exome-24 v1.0 BeadChip arrays (Illumina, San Diego, CA). Detailed information of the exome arrays and methods of quality control were described previously [40 (link)]. Totals of 41,371, 41,225, and 41,347 SNPs passed quality control in the EWASs for hypertriglyceridemia, hypo–HDL-cholesterolemia, and hyper–LDL-cholesterolemia, respectively, and were included in the analysis.